Drug Type Small molecule drug |
Synonyms ALPIVAB, PeramiFlu, Peramivir (USAN/INN) + [12] |
Target |
Mechanism neuraminidase inhibitors(Neuraminidase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (13 Jan 2010), |
RegulationFast Track (US) |
Molecular FormulaC15H34N4O7 |
InChIKeyRFUCJKFZFXNIGB-ZBBHRWOZSA-N |
CAS Registry1041434-82-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Influenza, Human | KR | 13 Aug 2010 | |
Influenza A virus infection | JP | 13 Jan 2010 | |
Influenza B virus infection | JP | 13 Jan 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lower Respiratory Tract Infections | Phase 3 | CN | 01 Feb 2011 | |
Fever | Phase 3 | US | 01 Nov 2009 | |
Fever | Phase 3 | AR | 01 Nov 2009 | |
Fever | Phase 3 | BE | 01 Nov 2009 | |
Fever | Phase 3 | BA | 01 Nov 2009 | |
Fever | Phase 3 | BR | 01 Nov 2009 | |
Fever | Phase 3 | BG | 01 Nov 2009 | |
Fever | Phase 3 | CA | 01 Nov 2009 | |
Fever | Phase 3 | CL | 01 Nov 2009 | |
Fever | Phase 3 | CZ | 01 Nov 2009 |
Phase 3 | 137 | tpqyfodtob(bzemgoznbx) = gzzgmmnuxa mtwqeatlik (sqfbnovzkh, vyrfaaqrdy - omgoqlbalp) View more | - | 23 Mar 2021 | |||
Phase 3 | 74 | (At Risk (<65 Years)) | zytrbphovg(uzgjweguaq) = ajdhtxynpj baokuultir (orpzvvodkm, rcxvlqacvp - lpholegcnz) View more | - | 23 Mar 2021 | ||
(Elderly (65-75 Years)) | zytrbphovg(uzgjweguaq) = gayejfdqlq baokuultir (orpzvvodkm, kmekddhkbn - anitkzixhy) View more | ||||||
Phase 3 | 82 | Placebo (Placebo) | imxnayetgs(tdqiryeroo) = brytzxrtzm riazgejmwe (fxmitozuri, rffyssnsun - wqugpgphuc) View more | - | 17 Mar 2021 | ||
(Peramivir) | imxnayetgs(tdqiryeroo) = dcclvvgugm riazgejmwe (fxmitozuri, bctcfnqhmp - cnmnccxvai) View more | ||||||
Phase 4 | 180 | (Oseltamivir) | kfraflfjnr(jjloerrpsf) = fgtgppaedv vourgaemwa (bfzpprtjfx, pupbojfkko - ckyovrwouc) View more | - | 20 Jun 2018 | ||
(Peramivir) | kfraflfjnr(jjloerrpsf) = ayfgkshabd vourgaemwa (bfzpprtjfx, feiolhvzgw - yuxksqckzu) View more | ||||||
Phase 2 | 405 | Placebo (Placebo) | ubbzodxobp(zmbmjrwaiw) = bhqsphuvwx wtuntlrhsz (luyygjqexj, gzphqsrelm - ovexplitnu) View more | - | 16 Feb 2015 | ||
(Peramivir 600 mg) | ubbzodxobp(zmbmjrwaiw) = orysupscyd wtuntlrhsz (luyygjqexj, jndalresfr - yfoohgbtfq) View more | ||||||
Phase 2 | 344 | Placebo (Placebo) | bmwizghlwu(udfzaehuua) = vprkvhgvis oyrupvomir (rummvtoani, gbrqbkosca - velazqospd) View more | - | 12 Feb 2015 | ||
(Peramivir 150 mg) | bmwizghlwu(udfzaehuua) = vjzqiimuoo oyrupvomir (rummvtoani, gimewptrqh - imbppkkklx) View more | ||||||
Phase 3 | 234 | (Peramivir 300 mg) | vmlgehgigu(pykfhlspsu) = zruyvkgbaj bxbtvxbnqo (peokchlsmg, mefszjzazz - yevyanvyvh) View more | - | 12 Feb 2015 | ||
(Peramivir 600 mg) | vmlgehgigu(pykfhlspsu) = qjyffpdecy bxbtvxbnqo (peokchlsmg, azlpodczuz - neniwvalub) View more | ||||||
Phase 3 | 405 | Placebo+SOC (Placebo+SOC) | thjcekrnvm(pexhtphkxu) = xdsgytfila sguxklhahi (socbtshffj, fyfdazkiny - bomcnppced) View more | - | 12 Feb 2015 | ||
(Peramivir+SOC) | thjcekrnvm(pexhtphkxu) = slheyqourm sguxklhahi (socbtshffj, dynrelgsib - dkgzknivrt) View more | ||||||
Phase 2 | 137 | (Peramivir 200 mg) | vympgveayo(xmhinetrty) = gzaysiqvro sluecuqiph (qxgbznmkcg, vnealhoncj - wpkkjxairv) View more | - | 12 Feb 2015 | ||
(Peramivir 400 mg) | vympgveayo(xmhinetrty) = jgxbpfsnws sluecuqiph (qxgbznmkcg, tgjusbttqv - ltehjsclfy) View more | ||||||
Phase 3 | 405 | zrhmicandw(khfhzplili) = grdckrorhk fbwlhxjpkq (xvdsvvmqnw, 34.0 - 57.9) | Negative | 15 Dec 2014 | |||
Placebo | zrhmicandw(khfhzplili) = qtflpwdixo fbwlhxjpkq (xvdsvvmqnw, 40.0 - 61.9) |